Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-20-0166
Abstract: After significant effort over the last 30 years, antibody–drug conjugates (ADC) have recently gained momentum as a therapeutic modality, and nine ADCs have been approved by the FDA to date, with additional ADCs in late… read more here.
Keywords: drug; bystander effect; antibody drug; dolaflexin ... See more keywords